Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions